High‐intensity statin therapy is associated with reduced coronary inflammation on CT in patients with type 2 diabetes mellitus
Diabetes, Obesity and Metabolism · 2025
DOI: 10.1111/dom.70032 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, 2025. Verfasst von Bryan Wu und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiovascular Medicine, Stanford University, Stanford, California, USA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Coronary Artery Disease, Inflammation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Stanford Cardiovascular Medicine Innovation Grant.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aims
Pericoronary adipose tissue (PCAT) attenuation, assessed by coronary computed tomography angiography (CCTA), is a biomarker of coronary inflammation. Mean PCAT attenuation ≥ −70.5 Hounsfield Units (HU) corresponds to elevated inflammation and a higher future risk of myocardial infarction. While statins are known to possess anti‐inflammatory properties, the impact of statin intensity on vascular inflammation remains underexplored in patients with type 2 diabetes mellitus (T2DM) and coronary atherosclerosis. We aim to evaluate whether high‐intensity statins are associated with lower PCAT attenuation in this high‐risk cohort. Materials and Methods We retrospectively analysed 203 CCTAs performed at our institution between 1/1/2019 and 9/1/2024 in patients with T2DM who met these key criteria: evidence of coronary atherosclerosis on CCTA, treatment with ≥1 oral hypoglycaemic agent, and no history of prior coronary interventions. PCAT attenuation was measured in the proximal right coronary artery.
Results
Among the three statin intensity groups, patients receiving high‐intensity statins ( n = 75) had the lowest PCAT attenuation (high‐intensity: −75.0 ± 6.8 HU, moderate‐intensity: −71.8 ± 8.2 HU, no statin: −71.6 ± 7.4 HU; adjusted p = 0.027). In addition to high‐intensity statins, treatment with glucagon‐like peptide‐1 receptor agonist was independently associated with a lower likelihood of having elevated PCAT attenuation (≥ −70.5 HU), with an odds ratio of 0.344 (95% CI: 0.132–0.900).
Conclusions
In patients with T2DM and coronary atherosclerosis, high‐intensity statin therapy was associated with lower coronary inflammation. Our findings emphasize the need for aggressive cardiovascular prevention in this high‐risk cohort.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Cardiovascular Medicine, Stanford University, Stanford, California, USA.
ORCID-Profile: Bryan Wu
Förderung
- Stanford Cardiovascular Medicine Innovation Grant
Zitieren
APA
Wu, B., Nieman, K., & Sandoval, R. (2025). High‐intensity statin therapy is associated with reduced coronary inflammation on CT in patients with type 2 diabetes mellitus. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.70032
Vancouver
Wu B, Nieman K, Sandoval R. High‐intensity statin therapy is associated with reduced coronary inflammation on CT in patients with type 2 diabetes mellitus. Diabetes, Obesity and Metabolism. 2025. doi:10.1111/dom.70032
BibTeX
@article{Wu2025,
author = {Wu, Bryan and Nieman, Koen and Sandoval, Ryan},
title = {High‐intensity statin therapy is associated with reduced coronary inflammation on CT in patients with type 2 diabetes mellitus},
journal = {Diabetes, Obesity and Metabolism},
year = {2025},
doi = {10.1111/dom.70032}
}
EUVIMED